Three former Palantir executives walked away from one of Silicon Valley's most secretive companies to build software for an industry arguably even more opaque: pharmaceutical drug development. Now, with $12 million in seed funding, they're betting that the pharmaceutical giants are finally ready to let artificial intelligence take the wheel.
Perceptic came out of stealth in 2026 with seed funding led by Accel, joined by Air Street Capital and Elder Gull. But unlike the typical seed-stage startup pitching a product demo and a dream, the London-based company had already landed deployments with several major pharmaceutical firms—including CSL, a global biopharmaceutical player, and what the founders describe as "several" top-20 pharma companies they're not yet naming.
That's unusual traction for such an early-stage venture, and it hints at something the pharmaceutical industry doesn't often advertise: desperation.
Drug development remains stubbornly slow and breathtakingly expensive. A single drug can take more than a decade to bring to market and burn through billions of dollars, with failure rates that would bankrupt most industries. Pharma executives have been hearing promises about AI-powered breakthroughs for years now, yet the fundamental timeline hasn't budged much. Perhaps that's why some of the biggest names in the business are willing to give Perceptic's platform a try before the company has even fully explained what it does.
The Palantir Pedigree
Tilman Flock, Martin Copes, and Zaki Trache—Perceptic's co-founders—spent years embedded in Palantir's Life Sciences and AIP divisions, where they built enterprise software for organizations with labyrinthine workflows and zero tolerance for error. Flock, now CEO, brings that same operational rigor to pharmaceuticals, an industry where a single misstep in clinical trial design can cost hundreds of millions.
The founders describe their product as an "AI operating system" for drug development, automating workflows across the entire pipeline—from early discovery through clinical trials. The specifics remain vague, which is typical for a company just stepping into public view. What's less typical is having paying customers already using it in production.
At the time of the announcement, Perceptic employed around 20 people, with engineering centered in London and most customers based in the United States. That footprint may shift as the company scales, assuming the seed capital lasts long enough to prove the model works at larger pharmaceutical organizations.
Why Now?
Accel's willingness to lead the round suggests venture investors see pharmaceutical AI infrastructure as a category in its own right, not just a feature that incumbents will eventually bolt onto existing systems. Air Street Capital, known for backing technical AI companies, adds credibility to the technical thesis.
But the pharmaceutical industry has seen wave after wave of AI startups promising to revolutionize drug discovery. Many fizzled. Some sold for modest sums. A few pivoted into adjacent markets when the core thesis didn't pan out. The difference this time—maybe—is that the founders understand enterprise software deployment at scale, not just the science.
Pharma companies are notoriously slow adopters, bound by regulatory constraints and institutional caution. Getting one major pharmaceutical firm to use your software is hard. Getting several to do so before you've raised a Series A? That suggests either the problem has reached a tipping point, or these particular founders know how to navigate procurement cycles that have broken other startups.
What Comes Next
With $12 million in the bank, Perceptic faces the classic post-seed challenge: moving from a handful of early believers to broader market adoption. Pharmaceutical sales cycles stretch across quarters, sometimes years. Validation requirements are exhaustive. And convincing a risk-averse industry to trust AI with billion-dollar drug pipelines will require more than elegant software.
Still, the founders have bought themselves time, and they've done so with customer traction that most seed-stage companies can only imagine. Whether that translates into the kind of transformational impact the pharmaceutical industry desperately needs—well, that story is still being written.
